West Pharmaceutical Services, Inc. Watch

from 10-Q 61 pages 1 Form of Stock Option Agreement West Pharmaceutical Services, Inc. 2016 Omnibus Incentive Compensation Plan West Pharmaceutical Services, Inc. (The “Company”), Pursuant to Its 2016 Omnibus Incentive Compensation Plan (The “Plan”), Hereby Grants to the Optionee Set Forth Below, the Number of Stock Options (The “Options”) Below, Subject to the Vesting and Other Terms and Conditions Set Forth Herein to Purchase Shares of Common Stock of the Company (“Share”). the Options Are Subject to All of the Terms and Conditions in the Plan, in This Stock Option Agreement (Including Its Exhibits) and in the Country-Specific Provisions for NON-U.S. Optionees (“Appendix A”), All of Which Are Incorporated Herein in Their Entirety. the Stock Option Agreement and Appendix a Are Referred to Collectively as the “Agreement.” Optionee: [Insert Optionee Name] Grant Date: [Insert Grant Date] Exercise Price Per Share [Insert Exercise Price] Number of Shares Subject to Options [Insert Number of Shares] Type of Option Nonstatutory Stock Option Expiration Date [Insert Tenth Anniversary of Grant Date] if the Date of the Tenth Anniversary Is Not a Trading Day, the Expiration Date Will Be the Trading Day That Immediately Precedes the Tenth Anniversary Date. Vesting Schedule [Insert] Provided the Optionee Has Provided Continuous Active Employment or Service to the Company or a Subsidiary or Affiliate From the Grant Date Through Each Applicable Vesting Date (Or Such Later Date as May Result From Suspended Vesting as Provided Below). Vesting Will Continue in Accordance With the Vesting Schedule Set Forth Herein During a Leave of Absence That Is Protected by Applicable Laws, Provided That Vesting Shall Cease if and When the Leave of Absence Is No Longer Guaranteed by Applicable Laws. the Company May Suspend Vesting of the Options During Any Unpaid Personal Leave of Absence, Except as Otherwise Required by Applicable Laws

from 10-K 18 pages Material contract

from 10-K 8 pages Material contract

from 10-K 65 pages West Pharmaceutical Services, Inc. Non-Qualified Deferred Compensation Plan for Designated Employees Effective January 1, 2024 Important Note This Document Has Not Been Approved by the Department of Labor, Internal Revenue Service, or Any Other Governmental Entity. an Adopting Employer Must Determine Whether the Plan Is Subject to the Federal Securities Laws and the Securities Laws of the Various States. an Adopting Employer May Not Rely on This Document to Ensure Any Particular Tax Consequences or to Ensure That the Plan Is “Unfunded and Maintained Primarily for the Purpose of Providing Deferred Compensation to a Select Group of Management or Highly Compensated Employees” Under Title I of the Employee Retirement Income Security Act of 1974, as Amended, With Respect to the Employer’s Particular Situation. Fmr LLC, Its Affiliates and Employees Cannot Provide You With Legal Advice in Connection With the Execution of This Document. This Document Should Be Reviewed by the Employer’s Attorney Prior to Execution

from 8-K 9 pages Whereas, as of April 1, 2022, the Business of the Former Division, Exxonmobil Chemical Company (“Emcc”), Has Been Reorganized Into a New Division of Exxon Mobil Corporation, Namely Exxonmobil Product Solutions Company (“Empsc”) and Hence Effective as of April 1, 2022, Any References in the Agreement to “Exxonmobil Chemical Company,” “Emcc,” “Emcc/A” or Any Defined Term That Refers to Such Name Shall Be Deemed to Refer to “Exxonmobil Product Solutions Company,” “Empsc” or “Empsc/A,” the Division of Exxon Mobil Corporation Now Responsible for the Agreement; Whereas, the Parties Now Wish to Amend Certain Terms of the Agreement; Now Therefore, in Consideration of the Premises and the Mutual Covenants and Conditions Assumed by the Parties Hereto, It Is Agreed as Follows, Entering Into Effect as of January 1, 2024: 1. Section Products, Quantity, Price Shall Be Amended as Following: The Products Table Shall Be Deleted in Its Entirety and Replaced by the Following Table, Effective January 1, 2024: Products Quantity [Metric Tons/ Year] Container Package Year 2024 2025 2026 2027 2028 [*****] [*****] Minimum Maximum [*****] [*****] [*****] [*****] [*****] [*****] [*****] [*****] [*****] [*****] Leased Metal Crates, [*****] [*****] [*****] [*****] [*****] [*****] Leased Metal Crates [*****] Not Defined Leased Metal Crates the Other Provisions in This Section Remain Unchanged. 2. Section Pricing Shall Be Deleted in Its Entirety and Replaced by the Following: Pricing

from 8-K 164 pages Second Amendment and Joinder and Assumption Agreement Dated as of March 31, 2022 Among West Pharmaceutical Services, Inc., as the Company, and the Other Borrowers Party Hereto, West Pharmaceutical Services Holding Japan Godo Kaisha, as the Additional Borrower,

from 10-K 24 pages Material contract

from 10-K 21 pages Eric M. Green President and Chief Executive Officer Updated: November 3, 2020 Kimberly Mackay (Sent via Email & Ups Overnight) Re: Employment Offer Letter Dear Kim: We Are Very Pleased to Confirm Our Offer of Employment to You for the Position of Senior Vice President, General Counsel and Corporate Secretary This Letter Will Confirm the Entire Compensation Package to Be Provided to You Upon Joining West. in This Position, You Will Report Directly to Me and Be an Executive Officer, as Approved by the Board, Upon the Commencement of Your Employment With the Company ( . Your Expected Start Date Is November 30, 2020 or Another Mutually Agreed Upon Date. 1. Place of Employment and Relocation You Will Be Expected to Primarily Work From Our Exton, Pennsylvania Headquarters. When You Relocate, You Will Receive Our Normal Relocation Benefits and Be Subject to Our Relocation Policy as in Effect When Your Relocation Commences. as an Exception to Our Normal Policy, You Will Have 18 Months to Relocate. as an Officer of the Company, You Will Be Paid a Relocation Lump Sum Amount of 2 Mon Provided With Up to 90 Consecutive Days of Temporary Living. 2. Base Salary Your Initial Base Salary Will Be $430, Payroll Schedule. You Will Be Eligible for an Annual Merit Increase in the 2022 Planning Cycle. 3. Annual Incentive Compensation Effective as of January 1, 2021, You Will Participate in West Using Our Board Approved Corporate Metrics With an Annual Target Bonus of 60% of Base Salary in Accordance With the Terms of the Aip Document. 4. Sign-On Bonus You Will Be Paid a One-Time Sign-On Bonus Up to a Maximum of $225,000 to Replace Rfeiture Is Required). This Amount Will Be Subject to Applicable Tax Withholding and Will Be Made on the First Normal Payroll Date Following Commencement of Employment and Proof of Forfeiture. This Bonus Is Subject to a 2

from 10-Q 16 pages Libor Transition Amendment

from 8-K 1 page West Pharmaceutical Services, Inc. 2016 Omnibus Incentive Compensation Plan Amendment No. 1

from 10-Q 16 pages West Pharmaceutical Services, Inc. Non-Qualified Deferred Compensation Plan for Designated Employees (Amended and Restated Effective as of January 1, 2020, Except as Otherwise Noted Herein or Required by Applicable Law) Plan Document the West Pharmaceutical Services, Inc

from 10-K 25 pages First Amendment and Incremental Facility Amendment

from 8-K 25 pages Global Master Supply Agreement

from 8-K 3 pages Amendment Agreement

from 10-Q 6 pages Stock Option Award Agreement

from 10-Q 6 pages Performance Stock Unit (Psu) Award Agreement

from 10-K 14 pages West Pharmaceutical Services, Inc. Non-Qualified Deferred Compensation Plan for Designated Employees (Amended and Restated Effective as of December 1, 2018, Except as Otherwise Noted Herein or Required by Applicable Law) Plan Document the West Pharmaceutical Services, Inc. Non-Qualified Deferred Compensation Plan for Designated Employees

from 10-Q 3 pages This Letter (“Letter”) Is Intended to Memorialize the Agreement and Understanding Between West Pharmaceutical Services, Inc. (“West”) and Daikyo Seiko, Ltd. (“Daikyo”) Regarding Certain Commercial Terms Relating to the Amended and Restated Technology Exchange and Crosslicense Agreement (The “Crosslicense Agreement”) and the Distributorship Agreement (The “Distributorship Agreement,” And, Together With the Crosslicense Agreement, the “Agreements”), Each Dated Effective January 18, 2017

from 8-K 13 pages May 29, 2018 Bernard Birkett Re: Employment Offer Letter Dear Bernard

from 10-Q 11 pages Form of Change-In-Control Agreement